Peptichemio in pretreated patients with ovarian cancer

A. Paccagnella, F. Tredese, L. Salvagno, A. Brandes, V. C. Sileni, O. Daniele, A. Fornasiero, V. Fosser, O. Nicoletto, T. Maggino

Research output: Contribution to journalArticlepeer-review


From January 1978 to October 1982, 47 patients with histological diagnosis of epithelial cancer of the ovary received peptichemio (PTC) at a dose of 70 mg/m2 (maximum, 120 mg total) every 15 days. Forty-two patients are now evaluable: 27 with stage III and 15 with stage IV disease. All patients but four with stage IV disease had been pretreated and had received at least one drug combination (median, three drugs per patient, including alkylating agents). Before the administration of PTC, the tumor extension in the abdomen was carefully assessed in all patients: ten patients had residual tumor <2 cm in diameter, while 32 patients had tumor > 2 cm in diameter. Objective responses were obtained in ten patients (23.8%): six complete remissions and one partial remission were observed in stage III patients and one complete remission and two partial remissions were observed in stage IV patients. Of the ten responding patients, eight had tumors <2 cm in diameter before receiving PTC. The median duration of response was 16 months. The most frequent side effects were myelosuppression and phlebosclerosis. Bone marrow depression was a common finding after the third course in heavily pretreated patients. Accordingly, in these patients a schedule interval of 3 weeks should be more appropriate. Since most of the responders were in the 'small tumor' category, PTC appears to be an active drug in patients with ovarian cancer having small tumors (<2 cm). On the other hand, the response rate in a nonselected population of patients remains to be clearly defined with further studies.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalCancer Treatment Reports
Issue number1
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Peptichemio in pretreated patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this